Biomarkers and Pathology

One imperative part of Pathology in the assessment of bosom malignancy is biomarker testing, particularly the precise appraisal of the estrogen receptor (ER), progesterone receptor (PR), and Her2 status of a patient's bosom tumor. Biomarkers can be prognostic, prescient, or both. Prognostic biomarkers are free measures of forecast to such an extent that the nearness or nonappearance of the biomarker is connected with a patient's general clinical result (i.e., danger of repeat and mortality).

    Related Conference of Biomarkers and Pathology

    March 10-11, 2025

    3rd World Congress on Oral Cancer

    Paris, France
    March 24-25, 2025

    25th World Congress on Cancer and Diagnostics

    London, UK
    March 24-25, 2025

    10th World Conference on Breast and Cervical Cancer

    Paris, France
    April 07-08, 2025

    15th World Congress on Breast Cancer

    Vancouver, Canada
    June 16-17, 2025

    26th World Congress on Cancer Summit

    Amsterdam, Netherlands
    July 14-15, 2025

    5th World Congress on Breast Cancer

    Berlin, Germany
    October 20-21, 2025

    21st International Conference on Cancer Research

    Barcelona, Spain

    Biomarkers and Pathology Conference Speakers

      Recommended Sessions

      Related Journals

      Are you interested in